GE Healthcare Japan K.K.
University of Wisconsin-Madison Initiates First U.S. Clinical Evaluation of Photon-Counting CT Technology Using GE Healthcare’s Deep Silicon Detector
Starting December 2022
This press release is a translated version of the press release issued by GE Healthcare on November 21, 2022. The official language of this document is English, and the content and interpretation shall be in English. Please refer to the following URL for this document in English.
https://www.ge.com/news/press-releases/uw-madison-to-perform-the-first-us-evaluation-of-ge-healthcares-photon-counting-ct ・ GE Healthcare’s Photon Counting CT (PCCT) with photon counting technology using a deep silicon detector achieves breakthroughs in both spatial and spectral resolution at the same time, enabling imaging of the entire care area. Designed with the goal of increasing performance.
Researchers at the University of Wisconsin-Madison (UW-Madison) will begin a human-subject imaging study on GE Healthcare’s
latest-generation PCCT prototype in December 2022. This will be GE Healthcare’s first PCCT clinical evaluation site in the United States. ・ This project was made possible through close collaboration between Wisconsin-based medical institutions, academic institutions, and medical device manufacturers.
Waukesha, Wisconsin, November 21, 2022:
Researchers at UW-Madison, GE Healthcare’s first U.S. clinical evaluation site for industry-first silicon-based PCCT[i] Initiate PCCT scans on subjects with the goal of a useful imaging performance breakthrough.
The partnership comes nearly a year after GE Healthcare announced its first clinical evaluation with Sweden’s Karolinska Institute of Medical Sciences, during which the company has rapidly advanced its innovation and new prototypes, including: is developing.
Larger detectors that enable faster scan times
・ECG synchronized imaging function designed for coronary angiography ・Increased shooting speed to suppress blur due to movement [ii] “PCCT will provide the best CT imaging,” explains Dr. Meghan G Lubner, professor of radiology at the University of Wisconsin (UW) School of Medicine and Public Health. “This technology has the potential to expand the range of CT indications by combining fine energy
discrimination, high spatial resolution, noise reduction and soft tissue contrast enhancement. By photographing subjects with the new PCCT, we plan to evaluate and verify various issues, from improving image quality limitations that we are currently facing to contributing to solving clinical questions that have been out of reach until now. ” PCCT has the potential to further evolve CT, such as visualization of fine parts of organ structures, improvement of tissue
characterization, more accurate measurement and quantification of material density, and reduction of radiation exposure.
GE Healthcare has a unique approach to PCCT that simultaneously achieves higher spatial and spectral resolution through deep silicon detector purity, innovative geometric design, and Multi-bin technology for high performance spectral imaging. is being pursued. Through research conducted at UW-Madison, GE Healthcare hopes to better understand the potential of these unique technologies.
“PCCT advances CT technology in two ways: improved spatial resolution and improved contrast resolution,” said Dr. Tim Szczykutowicz, associate professor of radiology at the university. Dr.Szczykutowicz is also in the Department of Medical Physics and Bioengineering. “Photon counting technology is definitely the next big thing for CT. We are part of the evaluation and development process for this unique deep silicon PCCT.”
UW-Madison facilitates subject imaging and evaluation and provides technical feedback for the evaluation and advancement of GE
Healthcare’s PCCT technology. This study will evaluate PCCT’s more optimal reconstruction methods, image viewing workflows, and clinical utility in detailed pathologies and diseases.
Jean-Luc Procaccini, GE Healthcare MICT President & CEO, said: “Innovation requires close collaboration between medical technology innovators and academia. Together with UW and the Karolinska Institute of Medical Sciences, we are developing cutting-edge technologies to provide doctors and patients with more information, faster, all to help improve patient outcomes. ”
For more information on GE Healthcare’s unique approach to PCCT, please visit our website.
[i] Technologies currently in research and development, these technologies are not products. Not approved for drug use. Not licensed or approved for commercial use by the US FDA or any regulatory agency in any other country.
[ii] compared to previous prototypes.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improving outcomes for patients, providers, health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
Details about this release: